🇺🇸 FDA
Patent

US 10532050

Formulations of oxabicycloheptanes and oxabicycloheptenes

granted A61KA61K31/197A61K31/34

Quick answer

US patent 10532050 (Formulations of oxabicycloheptanes and oxabicycloheptenes) held by Lixte Biotechnology, Inc. expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Lixte Biotechnology, Inc.
Grant date
Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/197, A61K31/34, A61K31/4525, A61K31/496